These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 15083067)

  • 1. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes.
    Hesse LM; He P; Krishnaswamy S; Hao Q; Hogan K; von Moltke LL; Greenblatt DJ; Court MH
    Pharmacogenetics; 2004 Apr; 14(4):225-38. PubMed ID: 15083067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.
    Desta Z; Saussele T; Ward B; Blievernicht J; Li L; Klein K; Flockhart DA; Zanger UM
    Pharmacogenomics; 2007 Jun; 8(6):547-58. PubMed ID: 17559344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects.
    Robertson SM; Maldarelli F; Natarajan V; Formentini E; Alfaro RM; Penzak SR
    J Acquir Immune Defic Syndr; 2008 Dec; 49(5):513-9. PubMed ID: 18989234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.
    Hesse LM; Venkatakrishnan K; Court MH; von Moltke LL; Duan SX; Shader RI; Greenblatt DJ
    Drug Metab Dispos; 2000 Oct; 28(10):1176-83. PubMed ID: 10997936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.
    Kirchheiner J; Klein C; Meineke I; Sasse J; Zanger UM; Mürdter TE; Roots I; Brockmöller J
    Pharmacogenetics; 2003 Oct; 13(10):619-26. PubMed ID: 14515060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes.
    Court MH; Duan SX; Hesse LM; Venkatakrishnan K; Greenblatt DJ
    Anesthesiology; 2001 Jan; 94(1):110-9. PubMed ID: 11135730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex.
    Zhang H; Sridar C; Kenaan C; Amunugama H; Ballou DP; Hollenberg PF
    J Pharmacol Exp Ther; 2011 Sep; 338(3):803-9. PubMed ID: 21659470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developmental Expression of CYP2B6: A Comprehensive Analysis of mRNA Expression, Protein Content and Bupropion Hydroxylase Activity and the Impact of Genetic Variation.
    Pearce RE; Gaedigk R; Twist GP; Dai H; Riffel AK; Leeder JS; Gaedigk A
    Drug Metab Dispos; 2016 Jul; 44(7):948-58. PubMed ID: 26608082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of human CYP2B6-catalyzed bupropion hydroxylation by Ginkgo biloba extract: effect of terpene trilactones and flavonols.
    Lau AJ; Chang TK
    Drug Metab Dispos; 2009 Sep; 37(9):1931-7. PubMed ID: 19487249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans.
    Ilic K; Hawke RL; Thirumaran RK; Schuetz EG; Hull JH; Kashuba AD; Stewart PW; Lindley CM; Chen ML
    Drug Metab Dispos; 2013 Mar; 41(3):575-81. PubMed ID: 23238783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic Influence on Stereoselective Steady-State Disposition of Bupropion.
    Kharasch ED; Lenze EJ
    Drug Metab Dispos; 2024 Apr; 52(5):455-466. PubMed ID: 38467432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity.
    Kharasch ED; Mitchell D; Coles R
    J Clin Pharmacol; 2008 Apr; 48(4):464-74. PubMed ID: 18287571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.
    Faucette SR; Hawke RL; Lecluyse EL; Shord SS; Yan B; Laethem RM; Lindley CM
    Drug Metab Dispos; 2000 Oct; 28(10):1222-30. PubMed ID: 10997944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: comparison with rifampicin.
    Hesse LM; Sakai Y; Vishnuvardhan D; Li AP; von Moltke LL; Greenblatt DJ
    J Pharm Pharmacol; 2003 Sep; 55(9):1229-39. PubMed ID: 14604466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
    Xu C; Ogburn ET; Guo Y; Desta Z
    Drug Metab Dispos; 2012 Apr; 40(4):717-25. PubMed ID: 22232427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6.
    Mo SL; Liu YH; Duan W; Wei MQ; Kanwar JR; Zhou SF
    Curr Drug Metab; 2009 Sep; 10(7):730-53. PubMed ID: 19702527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of in vitro cytochrome P450 2B6 activity.
    Walsky RL; Obach RS
    Curr Protoc Toxicol; 2009; Chapter 4():Unit4.27. PubMed ID: 23045012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid clinical induction of bupropion hydroxylation by metamizole in healthy Chinese men.
    Qin WJ; Zhang W; Liu ZQ; Chen XP; Tan ZR; Hu DL; Wang D; Fan L; Zhou HH
    Br J Clin Pharmacol; 2012 Dec; 74(6):999-1004. PubMed ID: 22519658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.
    Nakajima M; Komagata S; Fujiki Y; Kanada Y; Ebi H; Itoh K; Mukai H; Yokoi T; Minami H
    Pharmacogenet Genomics; 2007 Jun; 17(6):431-45. PubMed ID: 17502835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The P450 oxidoreductase (POR) rs2868177 and cytochrome P450 (CYP) 2B6*6 polymorphisms contribute to the interindividual variability in human CYP2B6 activity.
    Gao LC; Liu FQ; Yang L; Cheng L; Dai HY; Tao R; Cao SP; Wang D; Tang J
    Eur J Clin Pharmacol; 2016 Oct; 72(10):1205-1213. PubMed ID: 27439448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.